RxDoctor Payments Data

Hankyu Chung, MD

Internal Medicine · San Jose, CANPI 1447367966

Payments from drug & device makers

$456in general payments, 2019–2025

Across 41 payments — averaging $11.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$159
  • Abbott$116
  • AstraZeneca$38
  • Novo Nordisk$33
  • Boehringer Ingelheim$27
  • Nestle Healthcare Nutrition Inc.$25
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$31469%
  • Education$14231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$456 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$41,321
Medicare patients
459
Services billed
723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$63,986
EliquisApixaban41$53,468
FarxigaDapagliflozin Propanediol21$34,771
OzempicSemaglutide12$30,058
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm16$5,379
Humalog Kwikpen U-100Insulin Lispro16$4,167
Atorvastatin Calcium314$3,323
Rosuvastatin Calcium158$2,957
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,773
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide51$2,118
Losartan Potassium157$2,028
Wixela InhubFluticasone Propion/Salmeterol21$1,897
Amlodipine Besylate214$1,876
Diclofenac Sodium41$1,655
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide121$1,519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$27$63,98640 claims
AstraZenecaFarxiga$38$34,77121 claims
Novo NordiskOzempic$33$30,05812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →